Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Chronic catatonic syndrome badly giving in to treatment (clinical observation)

Dorovskih Igor Vladimirovich, Oleneva Ekaterina Valeryevna, Potapov Igor Viktorovich, Oleychik Igor Valentinovich, Pavlova Tatyana Alekseevna.
FGKI 1586-th clinical military hospital of the defense Ministry RF
Federal state budgetary institution MNIIP − branch of "The federal medical research center of psychiatry and narcology of V. P. Serbsky" of the Ministry
Federal state budgetary institution "Scientific Center of Mental Health" Russian Academy of Medical Science

SUMMARY

This article provides an overview of the literature on the epidemiology, causes of hypotheses, pathogenesis, morphology and genetic predisposition to catatonic, one of the terrible, critical states in psychiatry. Contradictions and complexity of the diagnosis, classification catatonic syndrome are considered. Powered by clinical observation, reflecting the above-described difficulties nosological diagnosis, therapy and prognosis of catatonic sindroma.

Contact: ig.dorovskih@yandex.ru

References: 
  • 1. Avrutskii G.Ya., Neduva A.A. Lechenie psikhicheski bol'nykh. – M.: Meditsina, 1988. – 528 s.
  • 2. Alekseeva A.G., Tiganov A.S. Ostrye katatonicheskie pristupy pri shizofrenii // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 2014. – T. 114, № 12. – S. 36–41.
  • 3. Alfimov P.V., Oleneva E.V., Mosolov S.N. Prognosticheskie faktory terapevticheskoi effektivnosti klozapina pri shizofrenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 2. – S. 21–29.
  • 4. Barkhatova A.N. Osobennosti endogennogo yunosheskogo pristupoobraznogo psikhoza s katatonicheskimi rasstroistvami v strukture manifestnogo pristupa // Psikhiatriya. – 2005. – № 3. – S. 38–44.
  • 5. Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naya meditsina – klinicheskoi praktike) / pod red. S.N. Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – 1076 s.
  • 6. Dedkova A.E. Opyt effektivnogo primeneniya benzodiazepinov pri katatonii, oslozhnennoi zlokachestvennym neirolepticheskim sindromom (ZNS) // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2016. – № 2. – S. 22–26.
  • 7. Zhislin S.G. Ocherki klinicheskoi psikhiatrii. – M.: Meditsina, 1965. – 320 s.
  • 8. Karlson A., Lekrub'e I. Dofaminovaya teoriya patogeneza shizofrenii / per. s angl. pod red. S.N. Mosolova. – London: Taylor & Francis, 2004.
  • 9. Mezhdunarodnaya klassifikatsiya boleznei (10-i peresmotr). Klassifikatsiya psikhicheskikh i povedencheskikh rasstroistv. – SPb., 1994. – 303 s.
  • 10. Mosolov S.N. Nekotorye aktual'nye teoreticheskie problemy diagnostiki, klassifikatsii, neirobiologii i terapii shizofrenii: sravnenie zarubezhnogo i otechestvennogo podkhodov // Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. – 2010. – T. 110, № 6. – S. 4–11.
  • 11. Osadshii Yu.Yu., Voblenko R.A., Archakov D.S., Tarakanova E.A. Mesto benzodiazepinov v sovremennoi terapii psikhicheskikh rasstroistv (obzor dokazatel'nykh issledovanii) // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2016. – № 1. – S. 2–10.
  • 12. Psikhiatriya: nauchno-prakticheskii spravochnik / pod red. A.S. Tiganova. – M.: MIA, 2016. – 608 s.
  • 13. Rukovodstvo po psikhiatrii. V 2 t. / pod red. A.S. Tiganova. – M.: Meditsina, 2012. – T. 1. – 807 s.
  • 14. Snezhnevskii A.V. Rukovodstvo po psikhiatrii. V 2 t. – M.: Meditsina, 1983. – T. 1. – 480 s.
  • 15. Smulevich A.B. Nemanifestnye formy shizofrenii – psikhopatologiya i terapiya // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 2005. – T. 105, № 5. – S. 4–10.
  • 16. Abrams R., Taylor M.A. Catatonia. A prospective clinical study // Archives of General Psychiatry. – 1976. – Vol. 33. – P. 579–581.
  • 17. Akhondzadeh S., Tabatabaee M., Amini H. et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial // Schizophr. Res. – 2007. – Vol. 90. – P. 179–185.
  • 18. Akhtar S., Ahmad H. Ciprofloxacin-induced catatonia // Journal of Clinical Psychiatry. – 1993. – Vol. 54. – P. 115–116.
  • 19. Alisky J.M. Is the immobility of advanced dementia from of lorazepam-responsive catatonia? // American journal of Alzheimer’s Disease and Other Dementias. – 2004. – Vol. 19. – P. 213–214.
  • 20. American psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th edn) (DSM-V). – APA. – 2013.
  • 21. Arolt V., AmbreÌe O. The Question of pro-inflammatory immune activity in schizophrenia and the potential importance of anti-inflammatory drugs // Inflammation in Psychiatry – Mod Trends Pharmacopsychiatry. Basel, Karger, 2013. – Vol. 28. – P. 100–116.
  • 22. Arvin K.L., Han B.H., Du Y. et al. Minocycline markedly protects the neonatal brain against hypoxic.ischemic injury. Annals of Neurology – 2002. – Vol. 52. – P. 54–61.
  • 23. Barnes M.P., Saunders M., Walls T.J. et al. The syndrome of Karl Ludwig Kahlbaum // Journal of Neurology, Neurosurgery and Psychiatry. – 1986. – Vol. 49. – P. 991–996.
  • 24. Beckmann H., Fritze J., Franzek E. The influence of neuroleptics on specific syndromes and symptoms in schizophrenics with unfavurable long-term course. A 5-year-follow-up study of 50 chronic schizophrenics // Neuropsychobiology. – 1992. – Vol. 26, No. 1–2. – P. 50–58. – doi: 10.1159/000118896.
  • 25. Benazzi F. Parenteral clonazepam for catatonia // Can J Psychiatry. – 1991. – Vol. 36, No. 4. – P. 312.
  • 26. Benegal V., Hingorani S., Khanna S. Idiopathic catatonia: validity of the concept // Psychopathology. – 1993. – Vol. 26. – P. 41–46.
  • 27. Blumer D. Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings // Compr Psychiatry. – 1997. – Vol. 38, No. 4. – P. 193–201.
  • 28. Chaudhry I.B., Hallak J., Husain N. et al. Minocycline benefits negative symptoms in early schizophrenia: a randomized double-blind placebo-controlled clinical trial in patients on standard treatment // Journal of Psychopharmacology – 2012. – Vol. 26, No. 9. – P. 1185–1193.
  • 29. Daniels J. Catatonia: clinical aspects and neurobiological correlates // J Neuropsychiatry Clin Neurosci. – 2009. – Vol. 21, No. 4. – P. 371–380. – doi: 10.1176/appi.neuropsych.21.4.
  • 30. Dhossche D.M. Autism as early expression of catatonia // Medical Science Monitor. – 2004. – Vol. 10. – P. 31–39.
  • 31. Dhossche D.M., Wachtel L.E., Goetz M., Sienaert P. Catatonia in psychiatric illnesses / Fatemi H., Clayton P. (eds.). The Medical Basisof Psychiatry. – New York: Springer, 2014.
  • 32. Gingrich J.A., Rudnick-Levin F., Almeida C. et al. Cocaine and catatonia // American Journal of Psychiatry. – 1998. – Vol. 155. – P. 1629.
  • 33. . Hawkins J.M., Archer K.J., Strakowski S.M., Keck P.E. Somatic treatment of catatonia // Int J Psychiatry Med. – 1995. – Vol. 25, No. 4. – P. 345–369.
  • 34. Hung Y.Y., Huang T.L. Lorazepam and diazepam rapidly relieve catatonic feature s in major depression // Clin Neuropharmacol. – 2006. – Vol. 29, No. 3. – P. 144–147.
  • 35. Jablensky A., Sartorius N., Ernberg G. et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study // Psychol Med Monographs. – 1992. – Supp. 20. – P. 1–97.
  • 36. Kirubakaran V., Sen S., Wilkinson C.B. Catatonic stupor: unusual manifestation of temporal lobe epilepsy // Psychiatric journal of the University of Ottawa. – 1987. – Vol. 12. – P. 244–246.
  • 37. Lauer M., Schirmeister H., Gerhard A. et al. Distubed neural circuits in a subtype of chronic catatonic schizophrenia demonstrated by F-18-FDG-PET and F-18-DOPA-PET // Journal of Neural Trasmission. – 2001. – Vol. 108. – P. 661–670.
  • 38. Lee J.W., Schwartz D.L. Catatonia associated with hyponatremia // Neuropsychiatry, Neuropsychology and Behavioral Neurology. – 1997. – Vol. 10. – P. 63–64.
  • 39. Leonhard K. The classification of Endogenous Psyhoses (5th edn) / Transl. R. Berman. – Irvington, 1979.
  • 40. Levkovitz Y., Mendlovich S., Riwkes S. et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in ealy-phase schizophrenia // Journal of Clinical Psychiatry. – 2010. – Vol. 71. – P. 138–149.
  • 41. Lim J., Yagnik P., Schraeder P., et al. Ictal catatonia as a manesedtation of nonconvulsive status epilepticus // Journal of Neurology, Neurosurgery and Psychiatry. – 1986. – Vol. 49. – P. 833–836.
  • 42. Masi G., Mucci M., Floriani C. Acute catatonia after a single dose of ecstasy // Journal of the American Academy of Child and Adolescent Psychiatry. – 2002. – Vol. 41. – P. 892.
  • 43. Miyaoka T. Minocycline for Schizophrenia: A critical review // Open Journal of Psychiatry – 2012. – Vol. 2. – P. 399–406.
  • 44. Moskowitz A.K. “Scared stiff”: catatonia as an evolutionary-based fear response // Psyvhological Review. – 2004. – Vol. 111. – P. 984–1002.
  • 45. Mu¨ller N., Krause D., Dehning S. et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment // Schizophr Res. – 2010. – Vol. 121. – P. 118–124.
  • 46. Northoff G. Katatonie. Einfuhrung in die Phdnomenologie, Klinik und Pathophysiologie eines psychomotorischen Syndroms. – Stuttgart, Germany: Enke, 1997.
  • 47. Northoff G. What catatonia can tell us about ‘top-down modulation’: a neuropsychiatric hypothesis // Behavioural Sciances. – 2002. – Vol. 25. – P. 555–577.
  • 48. Osman A.A., Khurasani M.H. Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shutdown hypothesis // British Journal of Psychiatry. – 1994. – Vol. 165. – P. 548–550.
  • 49. Payee H., Chandrasekaran R., Raju G.V. Catatonic syndrome: treatment response to Lorazepam // Indian J Psychiatry. – 1999. – Vol. 41, No. 1. – P. 49–53.
  • 50. Pommepuy N., Januel D. [Catatonia: resurgence of a concept. A review of the international literature] (in French) // L’Encuphale. – 2002. – Vol. 28. – P. 482–492.
  • 51. Rosebush P.I., Hildebrand A.M., Furlong B.G. et al. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam // Journal of Clinical Psychiatry. – 1990. – Vol. 51. – P. 357–363.
  • 52. Schmider J., Standhart H., Deuschle M., Drancoli J., Heuser I. A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism // Biol Psychiatry. – 1999. – Vol. 46, No. 3. – P. 437–441. – doi: 10.1016/S0006O 3223(98) 00312O6.
  • 53. Sienaert P., Dhossche M., Van Sampfort D., DeHert M., GaWbor G. A clinical review of the treatment of catatonia // Front Psychiatry. – 2014. – Dec. 9. – Vol. 5. – P. 181. – doi: 10.3389/fpsyt.2014.00181.
  • 54. Starkstein S., Sabe S., Vasquez S. et al. Neuropsychological, psychiatric, and cerebral blood flow findings in vascular dementia and Alzheimer’s disease. – Stroke. – 1996. – Vol. 7. – P. 408–414.
  • 55. Stober G. Genetic predisposition and enviromental causes in periodic and systematic catatonia // European Archives of Psychiatry and Clinical Neuroscience. – 2001. – Vol. 251, Suppl. 1. – P. 121–124.
  • 56. Stober G., Franzek E., Haubitz I. et al. Gender differences and age of set in the catatonic subtypes of schizophrenia // Psychopathology. – 1998. – Vol. 31. – P. 307–312.
  • 57. Stober G., Sheelow D., Ruschendorf F. et al. Periodic catatonia: confirmation of linkage to chromosome 15 and further evidence for genetic heterogeneity // Human Genetics. – 2002. – Vol. 111. – P. 323–330.
  • 58. Taylor M. A., Fink, M. Catatonia in psychiatric classification: a home of its own // American Journal of Psychiatry. – 2003. – Vol. 160. – P. 1233–1241.
  • 59. Tebartz van Elst, Perlov E. Epilepsie und Psyche // Kohlhammer. – 2013. – Vol. 28. – P. 481–492.
  • 60. Ungvari G.S., Chiu H.F., Chow L.Y., Lau B.S., Tang W.K. Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study // Psychopharmacology (Berl). – 1999. – Vol. 142, No. 4. – P. 393–398. – doi: 10.1007/s002130050904.
  • 61. Ungvari, G.S., Leung, S.K., Ng F.S. et al. Schizophrenia with prominent catatonic features (‘catatonic schizophrenia’). I: Demographic and clinical correlates in the chronic phase // Progress in Neuropsychopharmacology and Biological Psychiatry. – 2005. – Vol. 29. – P. 27–38.
  • 62. Van Den Eede F., Sabbe B. Catatonia in psychiatric classification // American Journal of Psychiatry. – 2004. – Vol. 161. – P. 2327–2328.
  • 63. Wilcox J.A., Duffy P.R. The Syndrome of Catatonia // Behavioral Sciences. – 2015. – Vol. 5, No. 4. – P. 576–588.
  • 64. Wilcox J.A., Nasrallah H.A. Organic factors in catatonia // British Journal of Psychiatry. – 1986. – Vol. 149. – P. 782–784.
  • 65. Winokur G., Tsuang M.T. The natural history of mania, depression, and schizophrenia. – Washington, DC: American Psychiatric Press, 1996.
  • 66. Yeh A. W., Lee J. W., Cheng T. C. et al. Clozapine withdrawal catatonia associated with cholinergic and serotonergic rebound hyperactivity: a case report // Clinical Neuropharmacology. – 2004. – Vol. 27. – P. 216–218.